Price
$17.83
Increased by +2.89%
Dollar Volume
9.99 M
ADR%
6.98
Earnings Report Date (estimate)
Feb 27, 23 (N/A)
Market Cap.
472.37 M
Shares Float
22.82 M
Shares Outstanding
26.49 M
Beta
2.51
Price / Earnings
-2.37
BPR
163.65
20D Range
15.59 22.49
50D Range
13.73 24.65
200D Range
11.70 31.41
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -1.33
Increased by +35.12%
-1.81
Increased by +26.52%
Aug 9, 22 -0.82
Increased by +60.39%
-1.90
Increased by +56.84%
May 9, 22 -1.94
Increased by +9.77%
-1.44
Decreased by -34.72%
Feb 28, 22 -1.47
Decreased by -17.60%
-1.72
Increased by +14.53%
Nov 8, 21 -2.05
Decreased by -122.83%
-1.59
Decreased by -28.93%
Aug 9, 21 -2.07
Decreased by -276.36%
-2.15
Increased by +3.72%
May 10, 21 -2.15
Decreased by -220.90%
-1.25
Decreased by -72.00%
Mar 1, 21 -1.25
Decreased by -64.47%
-0.88
Decreased by -42.05%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 13.37 M
Increased by +568.12%
-35.27 M
Increased by +35.39%
Decreased by -263.79%
Increased by +90.33%
Mar 31, 22 5.24 M
Increased by +146.54%
-51.17 M
Increased by +9.19%
Decreased by -975.76%
Increased by +63.17%
Dec 31, 21 5.79 M
Increased by +158.89%
-38.66 M
Decreased by -24.30%
Decreased by -667.29%
Increased by +51.99%
Sep 30, 21 2.44 M
Increased by +4.46%
-54.08 M
Decreased by -157.49%
Decreased by -2.22 K%
Decreased by -146.51%
Jun 30, 21 2.00 M
Decreased by -13.82%
-54.58 M
Decreased by -431.82%
Decreased by -2.73 K%
Decreased by -517.14%
Mar 31, 21 2.13 M
Decreased by -19.61%
-56.35 M
Decreased by -476.31%
Decreased by -2.65 K%
Decreased by -616.94%
Dec 31, 20 2.24 M
Decreased by -24.60%
-31.10 M
Decreased by -183.05%
Decreased by -1.39 K%
Decreased by -275.37%
Sep 30, 20 2.33 M
Decreased by -29.69%
-21.00 M
Decreased by -182.58%
Decreased by -900.30%
Decreased by -301.88%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.